Showing papers in "The Breast in 2014"

TL;DR: The current data on the therapeutic management of HER2-positive breast cancer is reviewed, and recent guidance by the US Food and Drug Administration suggests that pathologic response to Her2-targeted therapy given preoperatively may allow an earlier assessment of their clinical benefit in the adjuvant setting.

TL;DR: This manuscript summarizes international consensus recommendations for the management of breast cancer in young women that were updated from BCY1 with incorporation of new evidence to inform the guidelines, and areas of research priorities were identified.

TL;DR: The most important parameter for treatment success and improved overall survival is the achievement of a pathologic complete response (pCR), although the role of pCR in patients with luminal A like tumours might be less informative.

TL;DR: Significant results are obtained that magnetic SLNB can be performed easily, safely and equivalently well in comparison to the radiotracer method, and a detection rate per patient higher for the SPIO tracer.

TL;DR: In elderly patients for whom chemotherapy is being considered, a CGA could be a useful addition to the decision-making process and the number of geriatric conditions correlated with grade 3-4 chemotherapy-related toxicity.

TL;DR: There is a lack of EB and MPI in the development of current breast apps, highlighting the need for regulation, full authorship disclosure and clinical trials, and a robust framework for identifying high quality applications is necessary.

TL;DR: Although little differences were seen in sexual functioning in the BCT group during prospective analyses and in comparison with healthy controls, analyses revealed that women who underwent a ME were at risk for post-operative sexual dysfunctions.

TL;DR: Ki67 expression identifies a subset of patients with Luminal B and node-positive breast cancer who could benefit from addition of adjuvant chemotherapy to hormonotherapy.

TL;DR: Serum levels of CEA and CA15-3 may differ in breast cancer molecular subtypes and preoperative levels of DFS and CEA have a significant effect on prognosis in Chinese women with breast cancer, andMultivariate analysis of prognosis indicated that C EA and CA 15-3 levels were independent prognostic factors for DMFS and DFS.

TL;DR: The present review highlights the potential relation between breast cancer treatments and sleep disturbances, particularly of chemotherapy, though more robust evidence is needed for a proper understanding of these associations.

TL;DR: In this paper, the authors studied predictors of central nervous system metastases (CNS-M) and outcome after CNS-M diagnosis according to tumor subtype and showed that the Lum/HER2+ subtype appears associated with the longest overall survival.

TL;DR: This systematic review examines current intraoperative methods for assessing margin status in breast conserving therapy for breast cancer and concludes that an ultrasound probe allows accurate examination of the margins and delivers results in a timely manner, yet it has a limited role with DCIS where calcification is present and in multifocal cancer.

TL;DR: Risk of CBC increases with length of time after the first breast cancer diagnosis in BRCA1/2 mutation carriers, and studies addressing the impact of treatment-related factors and clinical characteristics of the first Breast cancer on this risk are warranted.

TL;DR: Fulvestrant is a selective estrogen receptor down-regulator that has demonstrated activity and efficacy in patients with hormone receptor-positive breast cancer previously untreated or treated with hormonal therapy and the clinical data for different dosing regimens both alone or in combination with other drugs is critically assessed.

TL;DR: Breast cancer patients are common users of CAM concomitantly to their conventional cancer treatments and should be investigated regarding their current consumption of CAM, and they need advice evidence-based data on these treatments and potential interactions with on-going treatments.

TL;DR: A definitive prospective analysis of ER/PR/HER2 from a single center is presented and it is demonstrated that prevalence of receptor status from SSA is comparable with that in the West.

TL;DR: The distribution of Ki67 LIs in breast carcinomas diagnosed at different institutions by different pathologists using the method reflecting their daily practice was evaluated, and some currently used Ki67 LI cut off values are not realistic, and it is proposed to select more realistic values ending with 0 or 5.

TL;DR: This review gathers the information available about cardiac toxicity related to well-established systemic breast cancer treatments, as well as newer drugs, including antiangiogenics, mTOR inhibitors and novel anti-HER2 agents.

TL;DR: The results indicate patients receiving treatment for MBC are symptomatic with significant daily activity and/or WP impairment, and Symptom severity and interference, functional status, and overall HRQOL were moderately correlated with perceived work-related ability.

TL;DR: Integrated 2D/3D-mammography significantly increased cancer detection for both screening services; potential reduction in FPR is likely to differ between centres with those experiencing relatively higher FPR most likely to benefit from 2D/(3D)/3D mammography screening.

TL;DR: Findings suggest that Chk1 may represent a therapeutic target in TNBC, and provide a rationale to evaluate Chk 1 inhibitors in breast cancer patients.

TL;DR: Her2/HER3 co-overexpression is significantly associated with impaired OS from diagnosis of metastatic disease in patients with HER2-positive metastatic breast cancer, and co-inhibition of HER2 and HER3 or the inhibition of Her2/ HER3 hetero-dimerization may improve clinical outcome in this subgroup.

TL;DR: The results of this study support that Ghanaian women with diagnosed breast cancer have multiple addressable and modifiable patient factors that may deter them from completing the prescribed treatment.

TL;DR: There was no significant difference in compliance between Group A and Group B at 1 year, but higher compliance in patients receiving EMs was observed in Sweden/Finland, and compliance with initial AI and persistence rate were not significantly altered by EM.

TL;DR: Implementing a multidisciplinary breast cancer pathway leads to better compliance with the national guidelines and can improve breast cancer care.

TL;DR: This prognostic index may enable identification of patients with a poorer prognosis in whom more intensive systemic regimens may be appropriate and may also be considered in designing new trials, although it requires validation in other datasets before extrapolation to non-bevacizumab-containing therapy.

TL;DR: Developing future decision support tools for the assessment and management of breast cancer risk should address difficulties assessing risk, including a lack of available tools to standardize practice, and optimize translation of knowledge into clinical practice.

TL;DR: Considering the multiple pathways involved in the HR network, targeting other components of pathologically activated intracellular signaling in breast cancer may prove to be a new direction in clinical research.

TL;DR: The literature search including the non-English literature identified 66 articles with data on 123 cases of neuroendocrine tumours of the breast, including the own, and best management remains unknown.

TL;DR: An overview of all the molecular profiling studies that have been performed on IBC clinical samples to date is provided, using an unprecedented number of samples to search for gene signatures associated with survival and response to neo-adjuvant chemotherapy.